**Proteins** 

# **PLN-1474**


Cat. No.: HY-47888 CAS No.: 2408065-32-5 Molecular Formula:  $C_{24}H_{37}N_3O_4$ Molecular Weight: 431.57 Target: Integrin Pathway: Cytoskeleton

Storage: Powder -20°C

3 years 4°C 2 years

-80°C In solvent 6 months

> -20°C 1 month



**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO : ≥ 83.33 mg/mL (193.09 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3171 mL	11.5856 mL	23.1712 mL
	5 mM	0.4634 mL	2.3171 mL	4.6342 mL
	10 mM	0.2317 mL	1.1586 mL	2.3171 mL

Please refer to the solubility information to select the appropriate solvent.

# **BIOLOGICAL ACTIVITY**

Description	PLN-1474 (compound 1) is an orally active and selective ανβ1 integrin inhibitor with an IC50 value of <50 nM. PLN-1474 reduces levels of pSMAD3/SMAD3 in liver, hepatic collagen gene expression and hepatic OHP concentration in liver fibrosis mouse model. PLN-1474 can be used for the research of preventing, delaying or researching a fibrotic or cirrhotic disease or disorder.	
IC <sub>50</sub> & Target	IC50: ⊠50 nM (ανβ1), ⊠50 nM (ανβ6) <sup>[1]</sup>	
In Vitro	PLN-1474 inhibits $\alpha\nu\beta1$ and $\alpha\nu\beta6$ with IC <sub>50</sub> s of <50 nM by solid phase assay <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	PLN-1474 (10 $\mu$ M) decreases the expression level of profibrotic genes, including COL1A1 and TIMP1 in liver <sup>[1]</sup> . PLN-1474 significantly reduces levels of pSMAD3/SMAD3 in liver, hepatic collagen gene expression and hepatic OHP concentration in a mouse model of liver fibrosis <sup>[1]</sup> . PLN-1474 (6-12 weeks) prophylactically or therapeutically blocks SMAD3 phosphorylation and significantly decreases OHP	

levels, collagen gene expression, and collagen deposition examined histologically in the CDAHFD NASH mouse model  $^{[1]}$ . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **REFERENCES**

[1]. Anderson Kraig, et al. Combination treatment of liver diseases using integrin inhibitors. WO2021127483. 2021.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com